Edwards Lifesciences Corp (NYSE:EW) Shares Acquired by State of Wisconsin Investment Board

State of Wisconsin Investment Board boosted its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 6.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,989 shares of the medical research company’s stock after buying an additional 15,001 shares during the quarter. State of Wisconsin Investment Board owned 0.12% of Edwards Lifesciences worth $47,065,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Executive Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $25,000. FTB Advisors Inc. purchased a new stake in Edwards Lifesciences in the first quarter worth about $25,000. Sontag Advisory LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $26,000. Lindbrook Capital LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $27,000. Finally, Capital Financial Planning LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $28,000. 81.99% of the stock is owned by institutional investors.

In related news, VP Donald E. Bobo, Jr. sold 300 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $178.54, for a total transaction of $53,562.00. Following the completion of the sale, the vice president now directly owns 19,415 shares of the company’s stock, valued at approximately $3,466,354.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert W.A. Sellers sold 821 shares of the firm’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $175.36, for a total value of $143,970.56. Following the transaction, the vice president now owns 14,176 shares of the company’s stock, valued at $2,485,903.36. The disclosure for this sale can be found here. Insiders have sold a total of 140,184 shares of company stock valued at $25,114,297 over the last three months. Corporate insiders own 1.63% of the company’s stock.

EW has been the subject of a number of research reports. Raymond James lowered their price objective on shares of Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a research note on Wednesday, April 24th. Barclays upped their price objective on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a research note on Monday, March 25th. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. UBS Group boosted their target price on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Tuesday, March 12th. Finally, Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $188.10.

NYSE EW opened at $184.74 on Friday. The company has a fifty day moving average price of $179.62. Edwards Lifesciences Corp has a one year low of $134.53 and a one year high of $197.86. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.19. The firm has a market cap of $38.66 billion, a P/E ratio of 39.31, a P/E/G ratio of 2.39 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.09. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The business had revenue of $993.00 million during the quarter, compared to the consensus estimate of $989.87 million. During the same period last year, the company earned $1.22 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, research analysts predict that Edwards Lifesciences Corp will post 5.29 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: What is dividend yield?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.